Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Trauner

Showing results (701-710 of 777) with videos related to

Pageof 78
Sort By:
Hepatology (Baltimore, Md.)|January 21, 2019
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing CholangitisMichael Trauner, Aliya Gulamhusein, Bilal Hameed, et al.
Journal of Hepatology|January 23, 2022
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis GroupSimon Pape, Romée J A L M Snijders, Tom J G Gevers, et al.
Toxicology Letters|August 13, 2022
In vitro/in silico prediction of drug induced steatosis in relation to oral doses and blood concentrations by the Nile Red assayTim Brecklinghaus, Wiebke Albrecht, Julia Duda, et al.
Hepatology (Baltimore, Md.)|June 10, 2022
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASHJun Xu, Ya Wang, Mina Khoshdeli, et al.
Archives of Toxicology|August 13, 2022
Hypoalbuminemia affects the spatio-temporal tissue distribution of ochratoxin A in liver and kidneys: consequences for organ toxicityReham Hassan, Adrian Friebel, Lisa Brackhagen, et al.
JHEP Reports : Innovation in Hepatology|March 28, 2026
Response-guided bulevirtide ± pegylated interferon alfa-2a: long-term outcomes observed in the nationwide Austrian hepatitis D cohort studyMichael Schwarz, Marlene Hintersteininger, Caroline Schwarz, et al.
Hepatology International|June 2, 2021
Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver diseaseRafael Paternostro, Katharina Staufer, Stefan Traussnigg, et al.
Science Translational Medicine|August 13, 2025
FXR adapts hepatic mitochondrial function to increased substrate oxidation in patients with obesityKatrin Panzitt, Emilian Jungwirth, Lena E Vosko, et al.
Elife|October 28, 2024
Nuclear receptor corepressor 1 controls regulatory T cell subset differentiation and effector functionValentina Stolz, Rafael de Freitas E Silva, Ramona Rica, et al.
Hepatology (Baltimore, Md.)|July 14, 2020
Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver DiseaseGeorg Semmler, Teresa Binter, Karin Kozbial, et al.
Pageof 78

Showing results (701-710 of 777) with videos related to

Sort By:
Pageof 78
Hepatology (Baltimore, Md.)|January 21, 2019
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing CholangitisMichael Trauner, Aliya Gulamhusein, Bilal Hameed, et al.
Journal of Hepatology|January 23, 2022
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis GroupSimon Pape, Romée J A L M Snijders, Tom J G Gevers, et al.
Toxicology Letters|August 13, 2022
In vitro/in silico prediction of drug induced steatosis in relation to oral doses and blood concentrations by the Nile Red assayTim Brecklinghaus, Wiebke Albrecht, Julia Duda, et al.
Hepatology (Baltimore, Md.)|June 10, 2022
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASHJun Xu, Ya Wang, Mina Khoshdeli, et al.
Archives of Toxicology|August 13, 2022
Hypoalbuminemia affects the spatio-temporal tissue distribution of ochratoxin A in liver and kidneys: consequences for organ toxicityReham Hassan, Adrian Friebel, Lisa Brackhagen, et al.
JHEP Reports : Innovation in Hepatology|March 28, 2026
Response-guided bulevirtide ± pegylated interferon alfa-2a: long-term outcomes observed in the nationwide Austrian hepatitis D cohort studyMichael Schwarz, Marlene Hintersteininger, Caroline Schwarz, et al.
Hepatology International|June 2, 2021
Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver diseaseRafael Paternostro, Katharina Staufer, Stefan Traussnigg, et al.
Science Translational Medicine|August 13, 2025
FXR adapts hepatic mitochondrial function to increased substrate oxidation in patients with obesityKatrin Panzitt, Emilian Jungwirth, Lena E Vosko, et al.
Elife|October 28, 2024
Nuclear receptor corepressor 1 controls regulatory T cell subset differentiation and effector functionValentina Stolz, Rafael de Freitas E Silva, Ramona Rica, et al.
Hepatology (Baltimore, Md.)|July 14, 2020
Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver DiseaseGeorg Semmler, Teresa Binter, Karin Kozbial, et al.
Pageof 78